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ABSTRACT 
 
S100A1 Mediated Signaling in the Nervous System. (April 2011) 
 
Ilka Maza 
Department of Biomedical Science 
Texas A&M University 
 
Research Advisor: Dr. Danna Zimmer 
Department of Veterinary Pathobiology 
 
S100 proteins are a large family of Ca
2+
 binding protein that have been implicated in the 
onset and progression of neurological diseases such as Alzheimer’s disease (AD), 
cancer, and multiple sclerosis. However, the molecular mechanisms of altered S100 
signaling in these diseases have not been elucidated.  Recent studies from our laboratory 
demonstrate that one member of the family, S100A1, regulates amyloid precursor 
protein (APP) production and glycogen synthase kinase 3β (GSK3β) signaling in 
neuronal cell lines. In the brain, APP and GSK3β are involved in the development of 
senile plaques and tangles seen in AD and other dementias.  However, neuronal cell 
lines do not faithfully mimic the diverse cell types/subtypes and complex anatomical 
organization of the intact brain.  Therefore, this project uses a genetic approach to 
determine if S100A1 regulates amyloid precursor protein and GSK3β expression in the 
in vivo brain. S100A1
-/-
 and wildtype levels for APP are 0.58 ± 0.10 vs. 0.46 ± 0.07 and 
for phospho-GSK3β are 0.22 ± 0.07 vs. 0.27± 0.06. However, these differences are not 
  iv 
statistically significant. Thus, our study demonstrates that S100A1 does not regulate the 
in vivo levels of APP or GSK3β.  
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NOMENCLATURE 
  
Aβ Amyloid Beta 
AD Alzheimer’s Disease 
APP Amyloid Precursor Protein 
[Ca
2+
]i Intracellular Ca
2+ 
Levels 
EDTA  Ehtylene Diamine Triacetic Acid 
GSK3β Glycogen Synthase Kinase 3 Beta 
HRP Horseradish Peroxidase 
PVDF Polyvinylidene Difluoride 
SERCA Sarcoplasmic Endoplasmic Reticulum Calcium ATPase 
TBS Tris-buffered Saline 
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CHAPTER I 
INTRODUCTION 
 
Ca
2+
 signaling in the nervous system 
All cells use Ca
2+ 
as an intracellular second messenger. Cells maintain an intricate 
system of pumps and channels that maintain resting or basal Ca
2+ 
levels in the nanomolar 
range. In response to external stimuli, intracellular Ca
2+ 
levels ([Ca
2+
]i) increase to the 
micromolar range. Dysregulation of Ca
2+
 homeostasis is a hallmark of many diseases 
including neurological disorders (Berridge et. al., 2010). In the nervous system, calcium 
ions activate fundamental processes such as release of neurotransmitters, axonal flow, 
long-term potentiation, cell motility, secretion, differentiation, and apoptosis. For 
example, depolarization in the presynaptic neuron causes voltage gated Ca
2+
 channels to 
open, increasing [Ca
2+
]i levels which in turn triggers the release of neurotransmitters into 
the synaptic cleft. Changes in [Ca
2+
]i are transduced into biological responses by Ca
2+ 
binding proteins such as members of the S100/calmodulin/troponin superfamily. The 
long term goal of our research is to determine how S100A1, a member of the S100 
family, transduces changes in the [Ca
2+
]i into cellular responses and to develop agents 
that will inhibit the detrimental gain of S100A1 function that occurs in neurological 
diseases.  
_______________ 
This thesis follows the style of Journal of Neuroscience. 
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The S100 protein family 
The S100 proteins are a large family (>21 members) of Ca
2+
 binding proteins. These 
10,000 molecular weight proteins were named S100 because of their solubility in 100% 
ammonium sulfate (Zimmer et al., 2005). S100 proteins have no enzymatic function and 
exert their biological effects by interacting with and modulating the activity of other 
proteins (target proteins) (Zimmer et al., 1998). All S100 proteins contain a unique non-
canonical 14 amino acid EF-hand Ca
2+
 binding loop at the amino terminus (Zimmer et 
al., 2005). They also have a canonical 12 amino acid EF-hand Ca
2+
 binding loop at the 
carboxyl terminus that is found in all members of the S100/calmodulin/troponin 
superfamily (Figure 1) (Zimmer et al., 2005). 
 
 
  
 
Figure 1. S100 Ca
2+
 binding domains. The loop on the left illustrates the non-canonical 
N-terminal EF hand Ca
2+ 
binding domain that is unique to S100 family members with 
the amino acid sequence variations. In the middle we find a hinge region that connects 
both EF hands together. The loop on the right illustrates the canonical C-terminal EF-
hand Ca
2+ 
binding domain that is found in all members of the S100/calmodulin/troponin 
superfamily with the amino acid sequence variations.  
 
Ca
2+
 binding to these motifs results in a conformational change which exposes the 
hydrophobic patch needed for target protein binding. S100 family members regulate a 
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large number of diverse cellular processes that include phosphorylation, transcription 
factors, Ca
2+
 homeostasis, cell growth and differentiation, and inflammation (Zimmer et. 
al., 1995). S100 family members have also been implicated in Alzheimer’s disease, 
multiple sclerosis, Down’s syndrome, epilepsy and cancer (Zimmer et. al., 2005). 
 
S100A1 function  
S100A1 is expressed in many tissues and cells. In the heart, genetic ablation of S100A1 
impairs adaptation to hemodynamic stress, increases mortality in response to myocardial 
infarction, and results in hypertension (Desjardins et al., 2009). These effects have been 
attributed to S100A1 interaction with its target protein, the ryanodine receptor and 
SERCA pump (Desjardins et al., 2009).  In skeletal muscle, S100A1 ablation delays and 
decreases action potentials (Prosser et al., 2010).  The effects of S100A1 in skeletal 
muscle excitation-contraction coupling are due to S100A1 interaction with and 
modulation of the ryanodine receptor (Prosser et al., 2010). S100A1 is highly expressed 
in neuronal cells. Our lab was the first to report that S100A1 ablation in neuronal cells 
alters Ca
2+ 
homeostasis, dendrite formation, microtubule polymerization, amyloid 
precursor protein (APP) expression and sensitivity to the neurotoxic Aβ peptide (Figure 
2) (Zimmer et. al., 1998 and 2005). Thus, modulation of Ca
2+
 homeostasis by S100A1 
appears to occur in all cells types. 
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Figure 2. S100A1 binds Ca
2+ 
in neuronal cells. Calcium enters the cell and binds to 
S100 protein. Hydrophobic patch of S100 is exposed and calcium bound S100 binds to 
the target protein, forming an S100 target protein complex. This complex can go on to 
carry out cellular processes and cause biological effects. 
 
S100A1 regulation of APP 
More recently, our group has shown that S100A1 ablation/inhibition decreases 
Alzheimer’s disease pathology and increases cognitive function in an AD mouse model 
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(unpublished observations). The detrimental effects of S100A1 in AD may be due to 
increased APP expression. The APP gene is located on human chromosome 21q (Chow 
et. al., 2010). APP is also concentrated in synapses and has been implicated in synapse 
formation and repair (Chow et. al., 2010). In addition, it is up-regulated during cell 
differentiation and neuronal injury (Chow et. al., 2010).  There are two pathways for the 
proteolytic processing of APP, non-amyloidogenic or amyloidogenic. In the normal 
brain, the non-amyloidogenic pathway predominates (Chow et. al., 2010). APP is 
sequentially cleaved by α- and γ-secretases, which does not result in the production of 
the neurotoxic Aβ peptide (Chow et. al., 2010). In the AD brain, the amyloidogenic 
pathway predominates (Chow et. al., 2010). APP is sequentially cleaved by β- and γ-
secretases which results in Aβ peptide production (Chow et. al., 2010). The Aβ peptide 
aggregates and forms plaques, which are a pathological hallmark of AD (Chow et. al., 
2010). The beneficial effects of S100A1 ablation/inhibition on AD pathology are 
predicted to be attributable to decreases in APP/Aβ levels.  
 
S100A1 regulation of GSK3β 
Previous studies from our laboratory demonstrate that S100A1 signaling regulates 
glycogen synthase kinase-3β (GSK3β). GSK3β is responsible for regulating 
neurogenesis, axonal growth, and tau phosphorylation in the normal brain (Hur and 
Zhou, 2010). In the AD brain, GSK3β hyperphosphorylates the tau protein, resulting in 
the neurofibrillary tangles seen in AD patients (Hernández et al., 2010). GSK3β is 
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inactivated by AKT phosphorylation (Liang et al., 2003). Thus we predict that 
ablation/inhibition of S100A1 will increase phospho-GSK3β levels in the in vivo brain.  
 
Project description 
This project tests our central hypothesis that S100A1 regulates APP and phospho- 
GSK3β levels in the in vivo brain. Immunoblotting was used to compare APP and 
phospho- GSK3β levels in S100A1 knockout mice and wildtype littermate controls. 
Based on our previous in vitro studies, we expect that S100A1 knockout mice will 
exhibit a 30 percent reduction in APP levels and a 3-fold increase in phospho-GSK3β 
levels (Zimmer et. al., 2005). Collectively, these results will identify S100A1 as a 
therapeutic target for Alzheimer’s disease and other neurological disorders in which 
increased APP expression contributes to the disease process. 
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CHAPTER II 
METHODS 
 
Sample acquisition/processing 
Total brain lysates were prepared from S100A1 knockout (experimental) and wildtype 
littermates (control) mice by homogenizing 0.05 g wt weight per 1 mL of TPER 
containing 10 mM EDTA and 3X HALT inhibitor (Thermo Scientific, Rockford, IL). 
Homogenates were separated into soluble and insoluble fractions by centrifugation at 
14000 rpm for 1 minute at 4C. Supernatant was collected; aliquots were prepared, and 
stored at -80°C. Protein concentrations were determined by Bradford assay as previously 
described (Bradford, 1976).  
 
Immunoblotting 
Ten µg total protein in 4% (w/v) SDS, 0.075 glycerol, 1.2 mg/mL Bromophenol blue,1 
mM DTT, 40 mM Tris-HCL, pH 6.8 (Sample Buffer) was sized fractionated using a 4-
20% SDS-polyacrilamide gel(Bio-Rad, Hercules, CA). Precision Plus Protein WesternC 
Standard was used as size markers (Bio-Rad). Gels were transferred to a nitrocellulose 
membrane (Millipore, Billerica, MA) for 60 minutes at 30 Volts in a Bio-Rad Mini-
Protean Tetra System with  20% methanol in 0.096M Glycine and 0.0125 M Tris; pH 
8.3 (transfer buffer) and a refrigerant pack. Blots were blocked in 5% (w/v) non-fat dry 
milk, 0.1% (v/v) Tween 20, 200 mM NaCl, 50 mM tris, pH 7.5, Tris-buffered saline 
(TBS)  (Non-fat Dry Milk TBST ) for 60 min at room temperature. 
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Detection of proteins was performed by incubating in primary antibody for one hour at 
room temperature or overnight at 4°C. Primary antibodies included, a mouse monoclonal 
C-terminal Anti-APP antibody (1-500 dilution of, A8717, Sigma-Aldrich) that detects 
full length APP, a rabbit polyclonal Phospho-GSK3β antibody (1-250 dilution of, #9336, 
Cell Signaling Technology), a rabbit monoclonal GSK3β antibody (1-500 dilution of, # 
9315, Cell Signaling Technology).  After rinsing three times for five minutes in 20mM 
Tris, pH 8.0, 150 mM NaCl, and 0.05% Tween-20 (TBST), blots were incubated in a 
species-specific secondary antibody containing  1µL Streptactin HRP for one hour at 
room temperature. Secondary antibodies included HRP-labeled Goat anti-rabbit antibody 
(1:10,000; Bethyl, Montgomery, TX), and HRP-labeled Goat anti-mouse IgG (1:15,000, 
KPL) in non-fat dry milk and Precision Protein StrepTactin-HRP conjugate (Bio-Rad). 
After washing in TBST, antibody binding was visualized with a Super Signal West 
Femto Maximum Sensitivity Substrate (Thermo Scientific). 
 
For quantification, membranes were imaged using the ImageQuant LAS 4000 mini 
system. ImageQuant TL 7.0 software was used to quantify pixels in bands.  To minimize 
variability and loading error, β-actin was used to normalize measured band pixels. In the 
case of C-terminal antibody, the blot was cut between 50-75 kDal; the lower half was 
incubated in a mouse monoclonal β-actin antibody (1-3,000 dilution of, A1978, Sigma-
Aldrich), and HRP-labeled Goat anti-mouse IgG (1:15,000 dilution of, A90-116P, 
Bethyl Laboratories), while the upper half was incubated in C-terminal antibody. 
Normalization consisted of dividing the pixel area for each APP band by the pixel area 
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for each β-actin band for each blot. The measured pixel area of all S100A1 knockout 
blots after normalization was averaged as well as the wildtype blots.  For phospho-
GSK3β, blots were normalized to total GSK3β. Phospho-GSK3β was then divided by 
the total GSK3β as previously described for C-terminal APP. All data were expressed as 
the mean relative levels + SEM (n=4 (phospho-GSK3β) n=6 (APP) for S100A1-/- and 
wildtype). A t-test was used to determine the significance (p< 0.05) of difference 
between samples groups.  
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CHAPTER III 
RESULTS 
 
Quantification of APP levels 
Given the importance of APP in neurodegenerative diseases such as AD, we sought to 
determine if S100A1 regulated APP levels in the cortex. A western blotting procedure 
was used to quantify APP levels in the cortex of S100A1
-/-
 and wildtype mice.    First, a 
comparison of Amersham Basic, Amersham Plus, Amersham Advanced, West Pico, and 
West Femto chemiluminescent detection kits was performed. Serial dilutions of an HRP 
conjugated secondary antibody were immobilized on Amersham nitrocellulose and 
PVDF; and then detected with the various chemiluminescence reagents. The West Femto 
Kit and the nitrocellulose membrane exhibited the greatest sensitivity. Next, we 
compared two primary antibodies that detect full length APP: 22C11 and C-terminal 
antibody. Interestingly, the 22C11 antibody did not detect full length APP (~120 kDal). 
However, the C-terminal antibody did detect full length APP band (~120 kDal). A 
comparison of 1-500, 1-750, 1-2000, and 1-5000 dilution of C-terminal antibody 
indicated that 1-750 dilution was optimal. To minimize loading errors, β-actin was used 
to normalize measured levels of APP. Two β-actin antibodies were compared and 
optimized. A β-actin antibody from Bethyl laboratories did not detect the predicted 42 
kDal band. However, a β-actin antibody (1-3,000 dilution) from Sigma laboratories did 
recognize the 42 kDal β-actin band.  
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Following optimization, levels of full length APP were quantified in brain extracts from 
S100A1
-/-
 and wildtype control mice. Data were expressed as the mean relative APP 
levels + SEM (n=6). A Student T-test was assessed to determine the significance 
(p<0.05) of measured differences. S100A1
-/-
 and wildtype levels for APP are 0.58 ± 0.10 
vs. 0.46 ± 0.07 (Figure 3). However, these differences are not statistically significant.  
 
 
 
 
 
 
 
 
 
 
Figure 3. Full length APP levels in S100A1-/- and wildtype mice. Representative APP 
and β-actin immunoblots are shown in the left-hand panel.  The histograms on the right 
contain the mean APP levels + SEM (n=6) in S100A1
-/- 
and wildtype littermates 
normalized to β-actin levels. Although APP levels were higher in S100A1-/- mice, this 
difference was not statistically significant.  
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Phospho-GSK3β levels do not respond to S100A1 genetic ablation  
GSK3β hyperphosphorylates the microtubule-associated tau protein resulting in the 
neurofibrillary tangles seen in AD patients. Interestingly, from previous studies we know 
that S100A1 regulates AKT, a protein kinase that phosphorylates and inactivates GSK3β 
(Zimmer et al., 2005). Thus, we hypothesize that S100A1 ablation will increase 
phospho-GSK3β levels in vivo. In order to quantify levels of phospho-GSK3β we had to 
optimize the conditions. The chemiluminescence detection kit and membrane is same as 
previously mentioned. We also determined that lysates must contain phosphatase 
inhibitors for phospho-GSK3β (~ 46 kDal) detection. A comparison of 1-250, 1-500, and 
1-1000 dilution of phospho-GSK3β antibody indicated that 1-250 dilution was optimal. 
Total GSK3β (46 kDal) levels were used for normalization and a 1-250 dilution of 
primary antibody was optimal. Next, we measured and quantified amounts of phospho-
GSK3β in S100A1-/-and wildtype mice. Data were expressed as the mean relative 
phospho-GSK3β levels + SEM (n=4). A Student T-test was assessed to determine the 
significance (p<0.05) of measured differences. S100A1
-/-
 and wildtype levels for 
phospho-GSK3β are 0.22 ± 0.07 vs. 0.27± .06 (Figure 4). However, this difference was 
not statistically significant. 
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Figure 4. Phospho-GSK3β levels in S100A1-/- and wildtype mice. Representative 
phospho-GSK3β and GSK3β immunoblots are shown in the left-hand panel.  The 
histograms on the right contain the mean phospho-GSK3β levels + SEM (n=4) in 
S100A1
-/- 
and wildtype littermates normalized to total GSK3β levels. Although phospho-
GSK3β were lower in S100A1-/- mice, this difference was not statistically significant.  
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CHAPTER IV 
SUMMARY AND CONCLUSION 
  
From this study we concluded that S100A1 does not regulate APP production or GSK3β 
signaling despite previous in vitro studies. Previous in vitro studies from our laboratory 
demonstrate that S100A1 ablation causes a 30% reduction in APP levels and a 3-fold 
increase in phospho-GSK3β levels. These differing results emphasize the importance of 
studying S100A1function in in vivo systems. These discrepancies may be due to regional 
variation in S100A1 function. S100A1 is highly expressed in areas of the brain such as 
the olfactory bulb and the cerebellum (unpublished observations) and the cortex, which 
was used in this study, expresses low levels. Thus, in future studies S100A1 function in 
brain regions with higher expression must be examined. Another explanation is that, 
whole brain homogenates may mask any changes that occur in specific cell populations.  
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